WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE:AZN) today announced plans to conduct two new clinical studies as part of PARTHENON, AstraZeneca’s largest clinical trial program involving over 80,000 patients. The studies are designed to build scientific understanding of BRILINTA® (ticagrelor) tablets in additional high-risk patient populations.
Help employers find you! Check out all the jobs and post your resume.
